



ZFW

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT

Docket Number:
11245/46405

Application Number
10/661,881

Filing date
September 11, 2003

Examiner
Anne L. Holleran

Art Unit
1642

Invention Title

**TREATMENT OF HUMAN TUMORS
WITH RADIATION AND INHIBITORS
OF GROWTH FACTOR RECEPTOR
TYROSINE KINASES**

Inventor(s)
WAKSAL, et al.

Address to:


Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 are enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Respectfully submitted,

Dated: June 28, 2006

By:


Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON LLP
One Broadway
New York, NY 10004
Tel: (212) 425-7200
Fax: (212) 425-5288
CUSTOMER NO. 26646



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
PTO - 1449 FORM**

ATTY. DOCKET NO.
11245/46405

SERIAL NO.
10/661,881

APPLICANT
WAKSAL et al.

FILING DATE
September 11, 2003

GROUP
1642

U. S. PATENT DOCUMENTS

EXAMINER R INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCL ASS	FILING DATE*
	4,863,902	September 5, 1989	Amagase et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 332 424	March 25, 1992					

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Bonner, J.A., et al., "The Interaction of Epidermal Growth Factor and Radiation in Human Head and Neck Squamous Cell Carcinoma Cell Lines With Vastly Different Radiosensitivities", Int. J. Radiation Oncology Biol. Phys., Vol. 29 No. 2, pp.243-247, 1994
	Huang, S., et al., ABSTRACT in Proceedings of the American Association for Cancer Research Vol. 39, March 1998
	Huang, SM, et al., "Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation, Apoptosis, and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck ¹ ", Cancer Research, Vol. 59, pp. 1935-1940 April 15, 1999
	Messa, C., et al., "EGF, TGF- α and EGF-R in Human Colorectal Adenocarcinoma", Acta Oncologica, Vol. 37, No. 3, pp. 285-289, 1998
	Real, F.X., "Expression of Epidermal Growth Factor Receptor in Human Cultured Cells and Tissues: Relationship to Cell Lineage and Stage of Differentiation ¹ ", Cancer Research Vol. 46, pp. 4726-4731, September 1986
	Masui, H., et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Moloclonal Antibodies ¹ ", Cancer Research Vol. 44, pp. 1002-1007, March 1984
	Goldstein, N.I., et al., "Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Model", Clinical Cancer Research, Vol. 1, pp. 1311-1318, November 1995
	Wells, W., et al., "EGF Receptor and p185 ^{erbB-2} -Specific Single-Chain Antibody Toxins Differ in Their Cell-Killing Activity on Tumor Cells Expressing Both Receptor Proteins" Int. J. Cancer, Vol. 60, pp. 137-144, 1995
	Moyer, J.D., "Induction of Apoptosis and Cell Cycle Arrest by CP-358, 774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase" Cancer Research Vol. 57, pp. 4838-4848, November 1, 1997
	Prewett, M., "The biologic Effects of C225, A Chimeric Monoclonal antibody to the EGFR, on Human Prostate Carcinoma", Journal of Immunotherapy, Vol. 19, No. 6, pp. 419-427, 1997
	Baselga, J., and Mendelsohn, J., "The epidermal growth factor receptor as a target for the therapy in breast carcinoma", Breast Cancer Research and Treatment, Vol. 29, pp. 127-138, 1994
	Baselga, J., et al., "Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal antibodies", Journal of the National Cancer Institute, Vol. 85, No. 16, August 18, 1993

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	